10-Q: Quantum-Si Reports Increased Losses Amid Restructuring

Quantum-Si Incorporated reported a significant increase in net loss for Q3 2025, driven by one-time lease termination and legal settlement expenses, despite successful capital raises.

Summary

• Net loss for the three months ended September 30, 2025, increased to $35.7 million, up from $25.3 million in the prior year, a 41.0% increase.
• For the nine months ended September 30, 2025, net loss was $83.7 million, compared to $67.9 million in the prior year, a 23.3% increase.
• Total revenue decreased by 29.9% to $552 thousand for the three months ended September 30, 2025, primarily due to longer capital sales cycles and budget cuts at certain customers.
• Total revenue for the nine months ended September 30, 2025, increased by 6.4% to $1.985 million.
• Gross profit margin declined to 35.1% for the three-month period (from 46.6% in 2024) and to 51.9% for the nine-month period (from 53.1% in 2024).
• Operating expenses surged by 40.5% for the three months and 21.7% for the nine months, largely due to a $13.6 million lease termination expense and $5.2 million in legal settlement expenses (net of insurance proceeds).
• Net cash used in operating activities increased to $78.4 million for the nine months ended September 30, 2025, from $64.9 million in the prior year.
• The company successfully raised $93.5 million in net proceeds from direct equity and pre-funded warrant offerings in January and July 2025.
• Cash, cash equivalents, and marketable securities totaled $230.5 million as of September 30, 2025.
• An organizational restructuring in November 2024 resulted in a 23% workforce reduction, incurring $2.3 million in one-time cash charges for severance.

Sentiment

Score: 3

Explanation: While the company successfully raised capital and is innovating with new products, the significant increase in net loss, decline in Q3 revenue, and worsening operating cash flow, coupled with substantial one-time expenses, indicate ongoing financial challenges and a difficult path to profitability. The market's reception to the Platinum Pro and future Proteus platform will be critical, but current financial performance is weak.

Positives

• Successfully raised $93.5 million in net proceeds from direct equity and pre-funded warrant offerings in January and July 2025, bolstering liquidity.
• Maintained a strong liquidity position with $230.5 million in cash, cash equivalents, and marketable securities as of September 30, 2025.
• Reduced Research and Development expenses by $2.3 million (14.1%) for the three months ended September 30, 2025, and Selling, General and Administrative expenses by $1.6 million (12.8%) for the same period, indicating some cost control efforts.
• Launched the Platinum Pro benchtop sequencer in January 2025, with first shipments in March 2025, expanding product offerings.
• Announced the next-generation Proteus™ platform, estimated to launch in the second half of 2026, demonstrating continued innovation and a future product roadmap.
• Resolved significant legal and lease disputes, including a preliminary settlement for the Delaware Stockholder Litigation and the termination of the New Haven, Connecticut lease, removing future obligations and uncertainties.

Negatives

• Net loss significantly increased to $35.7 million for the three months ended September 30, 2025, up 41.0% from $25.3 million in the prior year.
• Net loss for the nine months ended September 30, 2025, increased to $83.7 million, up 23.3% from $67.9 million in the prior year.
• Total revenue decreased by 29.9% to $552 thousand for the three months ended September 30, 2025, primarily due to longer capital sales cycles and budget cuts from entities like the National Institute of Health (NIH).
• Gross profit margin declined to 35.1% for the three months ended September 30, 2025 (from 46.6% in 2024) and to 51.9% for the nine months (from 53.1% in 2024).
• Incurred substantial one-time expenses, including $13.6 million in lease termination expense and $5.2 million in legal settlement expense (net of insurance proceeds) for the nine months ended September 30, 2025.
• Net cash used in operating activities increased to $78.4 million for the nine months ended September 30, 2025, from $64.9 million in the prior year, indicating worsening operational cash burn.
• Accumulated deficit grew to $680.4 million as of September 30, 2025, from $596.6 million at December 31, 2024, reflecting ongoing unprofitability.
• Dividend and interest income decreased by $1.7 million (18.7%) for the nine months ended September 30, 2025, due to lower market interest rates and invested balances.

Risks

• The impact of international conflicts, pandemics, or epidemics on the business.
• The impact of general conditions in the global economy and financial markets, including changes in inflation, interest rates, tariffs, and retaliatory trade policies.
• The ability to maintain the listing of Class A common stock on The Nasdaq Stock Market LLC.
• Changes in applicable laws or regulations.
• The ability to raise future financing on acceptable terms or at all.
• The success, cost, and timing of product development and commercialization activities.
• The commercialization and adoption of existing products (Platinum line, consumable kits) and the success of any future products.
• The ability to obtain and maintain regulatory approval for products, and any related restrictions and limitations.
• The ability to identify, in-license, or acquire additional technology.
• The ability to maintain existing lease, license, manufacture, and supply agreements.
• The ability to compete with other companies in proteomic analysis, many of which have greater financial and marketing resources.
• The size and growth potential of the markets for products and services, and the ability to serve those markets.
• Estimates regarding future expenses, future revenue, capital requirements, and needs for additional financing.
• The company's financial performance and the ability to generate significant revenue to achieve profitability.
• The evolving regulatory framework for artificial intelligence and machine learning, potential for increased compliance costs, regulatory investigations, lawsuits, and competitive disadvantages due to unauthorized use or failure to realize benefits.
• The inability to fully offset higher costs from inflation through price increases or manufacturing efficiencies.
• Foreign currency translation risk if international operations expand significantly without hedging arrangements.

Future Outlook

The company expects to continue incurring negative operating cash flows on an annual basis for the foreseeable future until commercial operations scale. Management believes current cash, cash equivalents, and marketable securities, combined with product and service revenue, will be sufficient to fund operations for at least the next 12 months. Future capital requirements may vary based on product commercialization success, R&D efforts, sales and marketing expansion, inventory build, and potential acquisitions. The company plans to execute on its product roadmap, including the Proteus™ platform estimated to launch in the second half of 2026, which aims to provide single molecule, amino acid level resolution with higher sequencing output and automation.

Management Comments

• Management believes that the Company's cash, cash equivalents and marketable securities, together with revenue from the sales of its products and services, will be sufficient to fund its planned operations for at least the next twelve months from the date of the issuance of the accompanying unaudited Condensed Consolidated Financial Statements.
• Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through private and public equity offerings, debt financings, and/or potential future collaboration, license and development agreements.
• The Company will need to generate significant revenue to achieve profitability and it may never do so.
• We expect gross profit margin to be variable for the foreseeable future as we work through our continued commercialization efforts.
• Going forward, we anticipate debt or equity offerings will be the primary source of funds to support our operating needs and capital expenditures until we reach scale of our commercial operations.
• We expect to incur negative operating cash flows on an annual basis for the foreseeable future until such time that we can scale our revenue growth.

Industry Context

Quantum-Si operates in the rapidly evolving proteomics tools market, aiming to differentiate itself from legacy solutions like mass spectrometry (MS) by offering a platform designed for faster, more parallel protein sequencing at a lower instrument cost and with greater automation. The company's Next-Gen Protein Sequencing (NGPS) technology seeks to unlock significant biological information through improved resolution and unbiased access to the proteome. The launch of Platinum Pro and the planned Proteus™ platform indicate a strategy to continuously innovate and expand its offerings to address market needs for biomarker discovery, disease detection, and other applications. The mention of NIH funding constraints impacting capital sales cycles suggests a sensitivity to broader research funding trends and the competitive landscape for research funding.

Management Changes

Corporate Governance

Legal Proceedings

• **Delaware Stockholder Litigation**: A punitive class action lawsuit filed on May 16, 2024, alleging breach of fiduciary duty and unjust enrichment related to the Business Combination. A preliminary settlement was reached on July 22, 2025, resulting in an $8.0 million accrued liability and a $4.6 million insurance receivable, with a net expense of $3.4 million. Finalization is estimated to take 3-6 months.
• **Contract Manufacturer Matter**: A dispute with a former contract manufacturer, initially filed in Texas in October 2023 and refiled in Minnesota in January 2024. Settled in August 2025 with a payment of $1.8 million to the manufacturer, included in legal settlement expense.
• **Winchester Mutual Release Agreement**: A lawsuit filed on September 13, 2022, against Winchester Office LLC regarding lease reimbursements and delays. A Mutual Release Agreement was entered into on September 23, 2025, terminating the lease for 67,000 square feet in New Haven, Connecticut. This resulted in a $13.6 million lease termination expense, net.

Related Party Transactions

• The company previously had an Amended and Restated Technology Services Agreement (ARTSA) with 4Catalyzer Corporation (4C) and other participant companies controlled by Dr. Jonathan Rothberg (former Chairman, current director). This agreement was terminated on June 10, 2021.
• Expenses paid to 4C for month-to-month sublease arrangements for office and laboratory spaces and certain administrative expenses were $0.1 million for the nine months ended September 30, 2025 (down from $0.2 million in 2024).
• An Advisory Agreement with Dr. Jonathan Rothberg, effective November 1, 2022, for strategic advice and consulting. Compensation included an option to purchase 250,000 shares of Class A common stock granted in March 2023.
• Dr. Jonathan Rothberg, a director, entered into a Rule 10b5-1 sales plan on September 9, 2025, to sell up to 8,973,841 shares of Class A common stock between January 14, 2026, and January 14, 2027.

Stakeholder Impact

• **Shareholders**: Experienced dilution from recent equity offerings (July 2025 and January 2025 Registered Direct Offerings) and face potential future dilution from the new ATM offering. Increased net loss and negative operating cash flow could negatively impact share value. The resolution of legal and lease disputes removes some uncertainty, but a significant 10b5-1 selling plan by a director may signal a lack of insider confidence.
• **Employees**: The company underwent an organizational restructuring in November 2024, resulting in a 23% workforce reduction. The Chief Commercial Officer, Todd Bennett, is departing. Continued investment in R&D for new platforms like Proteus™ could create new opportunities for remaining employees.
• **Customers**: The launch of Platinum Pro and the planned Proteus™ platform offer new and enhanced proteomic sequencing solutions. However, the company noted longer capital sales cycles due to budget cuts (e.g., NIH), indicating challenges in customer acquisition and market demand.
• **Creditors**: The company maintains a substantial cash and marketable securities position ($230.5 million), which provides a strong buffer for meeting short-term obligations despite ongoing operating losses.
• **Suppliers**: The company noted experiencing certain constraints in product and material availability and increasing costs due to geopolitical conflicts, which could impact supplier relationships and procurement costs.

Next Steps

• Continue commercialization efforts for Platinum and Platinum Pro instruments and consumable kits.
• Further invest in research and development, particularly for the Proteus™ platform, estimated to launch in the second half of 2026.
• Scale revenue growth to reduce negative operating cash flows and move towards profitability.
• Potentially pursue additional private and public equity offerings, debt financings, and/or collaboration agreements to fund operations.
• Finalize the preliminary legal settlement for the Delaware Stockholder Litigation, which is estimated to take 3-6 months.
• Monitor and respond to evolving regulatory frameworks for AI and machine learning.

Key Dates

Recommendation

The company continues to report significant net losses and negative operating cash flow, with a notable increase in net loss for the quarter and nine-month period. Revenue growth is inconsistent, showing a decline in the most recent quarter, and gross profit margins are contracting. While the company has successfully raised capital, the ongoing need for financing, coupled with a significant 10b5-1 selling plan by a director, suggests a lack of confidence from insiders or a need for liquidity. The substantial one-time expenses related to lease termination and legal settlements, while resolving past issues, highlight operational challenges. Despite new product launches and a future roadmap, the current financial performance indicates a challenging path to profitability, making the stock a high-risk investment with limited near-term upside.

Keywords

Proteomics, Next-Gen Protein Sequencing, Platinum instrument, Platinum Pro, Proteus platform, Life sciences, Biomarker discovery, SEC filing, 10-Q, Financial results, Capital raise, Legal settlement, Lease termination, Research and development, Selling general and administrative, Artificial intelligence, Machine learning